Validation results presented at the Association for Molecular Pathology meeting demonstrate that the test can be implemented clinically, replacing existing FISH and PCR assays.
In Cell this week: integrated genomic analysis of adult soft tissue sarcoma, positive selection has greater role in cancer than negative selection, and more.
Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.
The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.
An epigenetic analysis showed that the tumors all shared a certain DNA methylation signature, but that methylation patterns varied between samples.
The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.
Rare germline mutations in cancer risk genes turned up in more than half of sarcoma patients tested by gene panel sequencing.
The UPenn-led study proposal calls for editing three genes in autologous T cells with CRISPR and includes preliminary data for on- and off-target editing.
An analysis of angiosarcoma-derived cell lines identified a NUP160-SLC43A3 fusion that subsequently turned up in aggressive primary tumor samples.
A five-gene signature was linked to both event-free survival and overall survival in individuals with a type of rhabdomyosarcoma missing a prognostically informative gene fusion.
A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.
South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.
In Science this week: the synthetic genetic system hachimoji, and more.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.